Abstract：Objective：To observe the clinical effect of Bufei Pingchuan prescription combined with salmeterol fluticasone for chronic obstructive pulmonary disease(COPD) of lung- kidney qi deficiency type at stable stage. Methods： A total of 100 cases of COPD patients of lung- kidney qi deficiency type at stable stage were selected and divided into the treatment group and the control group according to the random number table method，with 50 cases in each group. Both groups were given routine symptomatic treatment； the control group was additionally given the inhalation treatment with salmeterol fluticasone powder， and the treatment group was additionally treated with Bufei Pingchuan prescription based on the treatment of the control group. Both groups were treated for two months. The clinical effects，Chinese medicine syndrome scores，lung function indexes and immune function indexes in the two groups were compared. Results：The total effective rate was 94.00% in the treatment group，higher than that of 70.00% in the control group(P＜0.05). After treatment，Chinese medicine syndrome score in the treatment group was decreased when compared with that in the control group(P＜0.05)；the levels of forced expiratory volume in one second(FEV1)，forced vital capacity(FVC)，immunoglobulin M(IgM)，immunoglobulin G(IgG) and immunoglobulin A(IgA) and the values of FEV1/%pred in the treatment group were increased when compared with those in the control group(P＜0.05). Conclusion： The therapy of Bufei Pingchuan prescription combined with salmeterol fluticasone has a definite curative effect in treating COPD of lung- kidney qi deficiency type at stable stage， which can effectively relieve the clinical symptoms of patients，improve their lung function，and enhance the body immunity.